About CellBion
CellBion is a company based in Seoul (South Korea) founded in 2010. CellBion operates in a competitive market with competitors including ARTMS, NorthStar Medical Radioisotopes, Niowave, Nanovista and Ground Fluor Pharmaceuticals, among others.
- Headquarter Seoul, South Korea
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website cellbion.co.kr
- Legal Name Cellbion Co., Ltd
- Annual Revenue$1.35 M (USD)-15.05as on Dec 31, 2025
- Net Profit-$5.24 M (USD)-4.23as on Dec 31, 2025
- EBITDA-$5.17 M (USD)-14.66as on Dec 31, 2025
People of CellBion
1 people are tracked at CellBion (1 in leadership).
| Name | Role | Group |
|---|---|---|
Kweon Kim | President & CEO | Leadership |
Complete people profiles for CellBion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CellBion
CellBion is a publicly listed company on the KRX with ticker symbol 308430 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Oct 2024
- Listed onKRX: 308430
- Listed entityCellbion Co., Ltd
- Exchange sectorHealth technology
- ISINKR7308430008
- Share price12,810.00 KRW (-5.67% on the day) · 2026-10-12
- Market capitalisation175,253,302,460.00 KRW
- EPS (diluted, trailing year)-683.90 KRW
- Volume (last session)18,062
Financials of CellBion
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.95B KRW | -7.57B KRW | -7.47B KRW |
| 2024 | 2.29B KRW | -7.27B KRW | -6.51B KRW |
| 2023 | 1.47B KRW | -3.63B KRW | -4.43B KRW |
| 2022 | 1.76B KRW | -6.38B KRW | -4.54B KRW |
| 2021 | 916.9M KRW | -4.78B KRW | -3.57B KRW |
Detailed financial statements for CellBion
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of CellBion
CellBion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ARTMS, NorthStar Medical Radioisotopes, Niowave, Nanovista and Ground Fluor Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| artms.ca | 2013 | Vancouver, Canada | $26.58M | – | Radioisotope technologies and services are developed and provided by ARTMS. | |
| northstarnm.com | 2006 | Madison, United States | $15.09M | – | Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market | |
| niowaveinc.com | 2006 | United States | $9.95M | – | Devices and radioisotopes for nuclear imaging are provided by Niowave. | |
| nanovista.ca | 2015 | Toronto, Canada | $2.3M | – | Multimodal visualization agents are developed for image-guided interventions. | |
| gfpharma.com | 2012 | Lincoln, United States | – | – | Proprietary chemistry for pharmaceutical synthesis is developed by the company. | |
| atomicalchemy.us | 2017 | Idaho Falls, United States | $150,000 | – | Limited information available | |
| azisotopes.org | 2017 | Bunker Hill, United States | $58.33M | – | Radiopharmaceuticals for diagnostic imaging are developed and produced. | |
| vnir.life | 2017 | Bengaluru, India | $724,462 | – | Infrared fluorescence-based diagnostic molecules are developed for imaging. |
Detailed competitors of CellBion
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CellBion
The website of CellBion (cellbion.co.kr) receives about 3.8K visits a month.
- Monthly visits3.8K
▼ 24.7% vs previous month
Latest news on Cellbion
Complete news archive for CellBion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CellBion
10 companies that operate in the same segment as CellBion (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CellBion
CellBion was founded in 2010.
CellBion is headquartered in Seoul, South Korea.
Kweon Kim is the current CEO of CellBion.
Annual revenue of CellBion is $1.35M as on Dec 31, 2025.
CellBion was founded in 2010 in Seoul, South Korea, within the biotechnology sector. Radioisotope probes for imaging are produced, focusing on diagnostic agents for PET-CT, PET-MRI, and blood vessel imaging in atherosclerosis patients. Therapeutic applications are also developed, including treatments for cardio and cerebrovascular conditions. The technology is applied additionally in the food industry for various uses.
CellBion's top competitors include ARTMS, NorthStar Medical Radioisotopes and Niowave.
Yes, CellBion is publicly traded on KRX under the ticker symbol 308430.
CellBion operates through Cellbion Co,.Ltd..